Jennison Associates
ADMA icon

Jennison Associates’s ADMA Biologics ADMA Stock Holding History

Jennison Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44,640
Closed -$766K – 568
2024
Q4 		$766K Buy
44,640
+10,125
+29% +$190K ﹤0.01% 518
2024
Q3 		$690K Buy
+34,515
New +$537K ﹤0.01% 521

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

Jennison Associates's ADMA Position: Q1 2025 in Review

Jennison Associates sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 44,640 shares — an estimated $766K sold.

Jennison Associates first reported a position in ADMA in Q3 2024 and held it in 2 quarters. The position peaked at $766K in Q4 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

  • Jennison Associates reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
  • Jennison Associates sold 44,640 ADMA Biologics shares in Q1 2025, an estimated $766K.
  • Jennison Associates first reported a position in ADMA Biologics in Q3 2024 and held it in 2 quarters.
  • Jennison Associates's ADMA Biologics position peaked at $766K in Q4 2024.
  • 347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Jennison Associates's 13F filing for Q1 2025, filed 5 May 2025.